Form 4: Century Therapeutics Chief Technology Officer Sells Shares for Tax Obligations

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, Inc., sold 526 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Gregory Russotti, the Chief Technology and Manufacturing Officer of Century Therapeutics, Inc. (IPSC), reported a transaction on June 9, 2025.
• The transaction involved the sale of 526 shares of Common Stock at a price of $0.622 per share.
• The sale was executed with transaction code 'S', indicating a sale.
• The purpose of the sale was to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The filing explicitly states that such sales were automatic and not at the discretion of the Reporting Person.
• Following this transaction, Gregory Russotti directly beneficially owns 392,047 shares of Common Stock.
• Additionally, 92,773 shares are indirectly beneficially owned by Gregory Russotti via the Gregory Russotti 2021 Family Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were sold, it was a non-discretionary transaction for tax purposes, which is a routine event and does not signal a lack of confidence or negative outlook from the insider.

Positives

• The sale was non-discretionary and solely for the purpose of covering tax withholding obligations, which is a routine event for executives receiving equity compensation, indicating no lack of confidence in the company.

Negatives

• The transaction resulted in a reduction of Gregory Russotti's direct beneficial ownership by 526 shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, particularly for publicly traded companies where executives receive equity compensation. It does not provide specific insights into broader industry trends.

Related Party Transactions

• Gregory Russotti indirectly beneficially owns 92,773 shares through the Gregory Russotti 2021 Family Trust.

Stakeholder Impact

• Shareholders: Minimal direct impact as the transaction is small and non-discretionary, not signaling a change in company fundamentals or insider confidence.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding